Last reviewed · How we verify
NCT03818841
The Role of High-flow Nasal Cannula Therapy in the Treatment of Acute Carbon Monoxide Poisoning
NA trial testing High-flow nasal cannula device in Carbon Monoxide Poisoning in 96 participants. Status unknown.
1 February 2022
Quick facts
| Lead sponsor | Università degli Studi del Piemonte Orientale Amedeo Avogadro |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 96 |
| Start date | 1 February 2019 |
| Primary completion | 1 February 2022 |
| Estimated completion | 1 February 2022 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- High-flow nasal cannula device
- Non-rebreathing oxygen mask group
Conditions studied
- Carbon Monoxide Poisoning — all drugs for Carbon Monoxide Poisoning →
Sponsor
Università degli Studi del Piemonte Orientale Amedeo Avogadro
Who can join
18 and older, any sex, with Carbon Monoxide Poisoning. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to test whether oxygen therapy delivered through high-flow nasal cannula devices in patients admitted to the emergency department for acute carbon monoxide poisoning is superior to the non-rebreathing oxygen face mask therapy with a 15 L/minute oxygen flow (currently the first-line therapy), in terms of reduction of carboxyhemoglobin (COHb) concentration and delayed neurological sequelae incidence.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03818841
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Carbon Monoxide Poisoning
Currently open trials in the same condition.
- NCT06811675 — The Efficacy of Dexamethasone in Combination With N-acetylcysteine in Preventing Neurocognitive Sequelae Due to Carbon M · Phase 4 · recruiting
- NCT06549621 — Cardiotoxicity of Carbon Monoxide in Patients Treated With Hyperbaric Oxygen Therapy · recruiting
- NCT04975867 — Adjunct Targeted Temperature Management in Acute Severe Carbon Monoxide Poisoning · NA · active not recruiting
Other Università degli Studi del Piemonte Orientale Amedeo Avogadro trials
Trials by the same sponsor.
- NCT07471581 — Patient Satisfaction Study at AOU Maggiore Della Carità (SCORE) · not yet recruiting
- NCT07424209 — Hypnotic Communication in Cardiology: A Randomized Controlled Trial · NA · recruiting
- NCT06260202 — Nutrition Under Noninvasive Ventilation · completed
- NCT05630157 — Evaluation of Effectiveness of the Unplugged Program on Gambling Among Adolescents (GAPUnplugged) · NA · unknown
- NCT04412655 — Primary Angioplasty for STEMI During COVID-19 Pandemic (ISACS-STEMI COVID-19) Registry · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03818841 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Università degli Studi del Piemonte Orientale Amedeo Avogadro
- Last refreshed: 6 February 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03818841.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing